Auf dieser Seite
SVRA Savara, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 11, 2026
$4,81
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$3,3452-Wochen-Tief
$7,0152-Wochen-Hoch
Marktkapitalisierung (MRQ)
$988M
P/E
-9.1
EPS
$-0.53
Ihre Abzeichen
52W-Spanne
$3–$7
Analystenbewertung
BUY
Kursziel
$11
P/E
-9.1
ROE
-73.4%
Nettogewinnmarge
·
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
SVRA Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$4.81
Marktkapitalisierung (MRQ)
$988M
P/E
-9.1
EPS
$-0.53
ROE
-73.4%
Verschuldungsgrad (MRQ)
0.2
52W-Spanne
$3–$7
SVRA Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz·2016-12-31 → 2020-12-31
EPS$-0.532021-12-31 → 2025-12-31
Freier Cashflow$-101M2016-12-31 → 2025-12-31
Nettogewinnmarge·2016-12-31 → 2020-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | SVRA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -9.15-Jahres-Durchschnitt ≈-8.4 | ≈-8.4 | · | · | |
| K/B (MRQ) | 6.95-Jahres-Durchschnitt ≈3.3 | ≈3.3 | 4.9 | Überbewertet | |
| EV / EBITDA | -6.35-Jahres-Durchschnitt ≈-4.7 | ≈-4.7 | · | · | |
| Kurs / FCF (TTM) | -8.95-Jahres-Durchschnitt ≈-8.4 | ≈-8.4 | · | · | |
| Kurs / Cashflow (TTM) | -9.05-Jahres-Durchschnitt ≈-8.4 | ≈-8.4 | · | · | |
| EV / FCF (TTM) | -7.65-Jahres-Durchschnitt ≈-5.6 | ≈-5.6 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 4.95-Jahres-Durchschnitt ≈3.3 | ≈3.3 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | SVRA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| ROA | -51.0%5-Jahres-Durchschnitt ≈-35.2% | ≈-35.2% | -21.8% | Schwach | |
| ROE | -73.4%5-Jahres-Durchschnitt ≈-43.6% | ≈-43.6% | -15.4% | Schwach | |
| ROIC | -53.0% | · | -117.8% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | SVRA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 0.25-Jahres-Durchschnitt ≈0.2 | ≈0.2 | · | · | |
| Liquiditätsgrad (MRQ) | 10.15-Jahres-Durchschnitt ≈15.2 | ≈15.2 | 10.6 | Geringe Liquidität | |
| Quick Ratio | 11.65-Jahres-Durchschnitt ≈14.8 | ≈14.8 | 2.5 | Starke Liquidität | |
| Langfristige Schulden / Eigenkapital (MRQ) | 0.25-Jahres-Durchschnitt ≈0.2 | ≈0.2 | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-5.9%
Nächster Bericht
Nov 10, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 11, 2026 | $-0.16 | $-0.15 | -10.2% |
| 31. März 2026 | Mai 11, 2026 | $-0.15 | $-0.14 | -9.2% |
| 31. Dezember 2025 | $-0.13 | $-0.12 | -8.2% | |
| 30. September 2025 | $-0.14 | $-0.14 | -3.5% | |
| 30. Juni 2025 | $-0.14 | $-0.12 | -12.6% | |
| 31. März 2025 | $-0.12 | $-0.13 | 8.5% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | $257.0K | $0 | · | $0 | $400.0K | $54.0K | $0 | |
| SG&A Expense | $42M | $25M | $16M | $11M | $12M | $14M | $13M | $11M | $11M | $3M | $2M | $9M | |
| Operating Expenses | $124M | $103M | $60M | $39M | $41M | $50M | $79M | $70M | $30M | $11M | $6M | $29M | |
| Operating Income | $-124M | $-103M | $-60M | $-39M | $-41M | $-49M | $-79M | $-70M | $-30M | $-11M | $-6M | $-29M | |
| Interest Expense | · | · | · | · | · | · | · | · | $1M | $452.0K | $3M | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $122.0K | $130.0K | $69.0K | |
| Other Non-op | $5M | $7M | $5M | $689.0K | $-2M | $-315.0K | $852.0K | $1M | $-3M | $-332.0K | $-3M | $508.0K | |
| Pretax Income | $-119M | $-96M | $-55M | $-38M | $-43M | $-50M | $-78M | $-69M | $-33M | $-11M | $-9M | $-29M | |
| Income Tax | $0 | $9.0K | · | · | · | · | · | $-7M | $-4M | $-357.0K | $0 | $0 | |
| Net Income | $-119M | $-96M | $-55M | $-38M | $-43M | $-50M | $-78M | $-62M | $-30M | $-11M | $-9M | $-29M | |
| EPS (Basic) | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 | · | · | · | · | · | · | · | |
| Shares (Basic) | 222,387,531 | 198,191,936 | 165,204,652 | 152,771,817 | 133,919,145 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 222,387,531 | 198,191,936 | 165,204,652 | 152,771,817 | 133,919,145 | · | · | · | · | · | · | · | |
| EBITDA | $-124M | · | $-60M | $-39M | $-41M | $-49M | $-78M | $-70M | $-30M | $-36M | $-39M | $-29M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33M | $15M | $27M | $52M | $34M | $23M | $50M | $24M | $22M | $13M | $17M | $13M | |
| Short-term Investments | $203M | $181M | $136M | $74M | $127M | $59M | $72M | $87M | $72M | $0 | · | · | |
| Prepaid Expense | $6M | $6M | $4M | $3M | $4M | $3M | $2M | $3M | $4M | $840.0K | $1M | $1M | |
| Current Assets | $242M | $202M | $166M | $129M | $165M | $85M | $124M | $113M | $98M | $15M | $42M | $58M | |
| PP&E (Net) | $100.0K | $165.0K | $270.0K | $51.0K | $73.0K | $156.0K | $352.0K | $522.0K | $925.0K | $793.0K | $226.0K | $188.0K | |
| PP&E (Gross) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $565.0K | $532.0K | |
| Accum. Depreciation | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $851.0K | $504.0K | $339.0K | $344.0K | |
| Goodwill | · | · | · | · | · | $0 | · | $27M | $27M | $3M | $3M | $3M | |
| Other Non-current Assets | $84.0K | $242.0K | $387.0K | $116.0K | $251.0K | $250.0K | $673.0K | $131.0K | $131.0K | $131.0K | $183.0K | $353.0K | |
| Total Assets | $253M | $213M | $178M | $140M | $177M | $98M | $136M | $152M | $160M | $29M | $54M | $70M | |
| Accounts Payable | $6M | $5M | $4M | $1M | $1M | $3M | $3M | $4M | $3M | $536.0K | $3M | $1M | |
| Accrued Liabilities | $15M | $10M | $7M | $5M | $5M | $6M | $5M | $3M | $3M | $2M | $8M | $6M | |
| Current Liabilities | $20M | $15M | $11M | $6M | $15M | $8M | $11M | $7M | $6M | $3M | $23M | $8M | |
| Capital Leases | · | $100.0K | $200.0K | $50.0K | $100.0K | $100.0K | $300.0K | · | $297.0K | $579.0K | $25.0K | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | $7M | $2M | $3M | $3M | |
| Other Non-current Liabilities | $0 | $87.0K | $247.0K | $54.0K | $117.0K | $84.0K | $513.0K | $70.0K | · | · | · | · | |
| Total Liabilities | $50M | $41M | $37M | $32M | $32M | $33M | $35M | $44M | $40M | $21M | $30M | $12M | |
| Long-term Debt | $30M | $27M | $26M | $26M | $26M | $25M | · | · | · | · | · | · | |
| Total Debt | $30M | · | $26M | $26M | $26M | · | · | · | · | · | · | · | |
| Common Stock | $204.0K | $173.0K | $140.0K | $116.0K | $116.0K | $55.0K | $52.0K | $36.0K | $32.0K | $5.0K | $164.0K | $159.0K | |
| Retained Earnings | $-608M | $-489M | $-393M | $-339M | $-301M | $-258M | $-208M | $-130M | $-68M | $-38M | $-275M | $-235M | |
| AOCI | $-87.0K | $-750.0K | $-271.0K | $-605.0K | $5.0K | $942.0K | $-17.0K | $200.0K | $958.0K | $-591.0K | $-17.0K | $-25.0K | |
| Stockholders' Equity | $203M | $171M | $140M | $108M | $144M | $64M | $102M | $108M | $119M | $-36M | $-27M | $-18M | |
| Liabilities + Equity | $253M | $213M | $178M | $140M | $177M | $98M | $136M | $152M | $160M | $29M | $54M | $70M | |
| Shares Outstanding | 204,567,283 | 172,423,223 | 138,143,545 | 114,046,345 | 114,036,892 | 54,152,955 | 50,790,441 | 35,146,096 | 30,509,522 | 3,162,573 | 163,614,297 | 159,458,376 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $87.0K | $130.0K | $77.0K | $31.0K | $136.0K | $255.0K | $1M | $526.0K | · | $99.0K | $146.0K | $85.0K | |
| Stock-based Comp | $14M | $10M | $4M | $2M | $3M | $5M | $4M | $4M | $552.0K | $209.0K | $153.0K | $2M | |
| Deferred Tax | · | · | · | · | · | · | · | $-7M | $-3M | $-2M | · | · | |
| Other Non-cash | · | · | · | · | · | · | $28M | · | · | · | · | · | |
| Operating Cash Flow | $-101M | $-89M | $-51M | $-35M | $-40M | $-40M | $-45M | $-39M | $-28M | $-8M | $-5M | $-25M | |
| CapEx | $22.0K | $25.0K | $296.0K | $9.0K | $57.0K | $47.0K | $148.0K | $141.0K | $495.0K | $8.0K | $165.0K | $147.0K | |
| Investing Cash Flow | $-18M | $-40M | $-57M | $53M | $-69M | $9M | $16M | $-14M | $-69M | · | · | · | |
| Debt Issued | $30M | · | · | $26M | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $2M | · | · | $88.0K | · | · | · | · | $-4M | · | · | · | |
| Stock Issued | · | · | · | · | · | $2M | $30M | $505.0K | $2M | $20M | $2M | $30M | |
| Net Stock Activity | · | · | · | · | · | $2M | $30M | $505.0K | $2M | $20M | $2M | $30M | |
| Financing Cash Flow | $138M | $118M | $83M | $87.0K | $121M | $4M | $55M | $55M | $106M | · | · | · | |
| Net Change in Cash | $18M | $-11M | $-26M | $18M | $11M | $-27M | $26M | $2M | $9M | $-3M | $4M | $10M | |
| Taxes Paid | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-101M | · | $-51M | $-35M | $-40M | $-40M | $-45M | $-39M | $-29M | $-37M | $-33M | $-25M | |
| Levered FCF | · | · | · | · | · | · | · | · | $-30M | $-39M | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | -19182.9% | · | · | · | -28481.2% | · | · | |
| Net Margin | · | · | · | · | · | -19305.5% | · | · | · | -28203.1% | · | · | |
| Pretax Margin | · | · | · | · | · | -19305.5% | · | · | · | -30085.2% | · | · | |
| EBITDA Margin | · | · | · | · | · | -19182.9% | · | · | · | -28481.2% | · | · | |
| ROA | -51.0% | · | -34.5% | -24.1% | -31.4% | -42.4% | -54.2% | -39.4% | -31.6% | -100.1% | -63.9% | -45.6% | |
| ROE | -73.4% | · | -38.1% | -34.0% | -28.7% | -70.4% | -75.0% | -54.4% | -71.4% | 410.9% | -1425.5% | -53.9% | |
| ROIC | -53.0% | · | · | · | · | · | · | -56.9% | -22.4% | -350.2% | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.8 | · | 15.7 | 22.0 | 11.3 | 10.4 | 11.4 | 15.6 | 16.3 | 2.5 | 1.8 | 6.9 | |
| Quick Ratio | 11.6 | · | 15.3 | 21.5 | 11.0 | 10.1 | 11.2 | 15.3 | 15.7 | 1.8 | 1.0 | 4.2 | |
| Debt / Equity | 0.1 | · | 0.2 | 0.2 | 0.2 | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.1 | · | 0.2 | 0.2 | 0.1 | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | -25.8 | -17.1 | -65.3 | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.99 | · | $1.02 | $0.94 | $1.27 | $1.19 | $2.00 | $3.08 | $3.91 | $0.04 | $0.15 | $0.37 | |
| Cash Flow / Share | $-0.45 | · | $-0.31 | $-0.23 | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.16 | · | $0.19 | $0.46 | $0.30 | $0.42 | $0.98 | $0.69 | $0.73 | $0.03 | $0.14 | $0.22 | |
| EPS (TTM) | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | $257.0K | $0 | · | $0 | $400.0K | $54.0K | $0 | |
| Net Income TTM | $-119M | $-96M | $-55M | $-38M | $-43M | $-50M | $-78M | $-62M | $-30M | $-11M | $-9M | $-29M | |
| Market Cap | $1.23B | · | $649M | $177M | $141M | $62M | $228M | $266M | $453M | · | · | · | |
| Enterprise Value | $1.03B | · | $513M | $77M | $6M | · | · | · | · | · | · | · | |
| P/E | -11.4 | -6.4 | -14.2 | -6.2 | -3.9 | · | · | · | · | · | · | · | |
| P/S | · | · | · | · | · | 242.3 | · | · | · | · | · | · | |
| P/B | 6.1 | · | 4.6 | 1.6 | 1.0 | 1.0 | 2.2 | 2.5 | 3.8 | · | · | · | |
| P / Tangible Book | 6.1 | 3.1 | 4.6 | 1.6 | 1.0 | 1.0 | · | · | · | · | · | · | |
| P / Cash Flow | -12.2 | · | -12.7 | -5.1 | -3.5 | -1.6 | -5.0 | -6.8 | -16.0 | · | · | · | |
| P / FCF | -12.2 | · | -12.6 | -5.1 | -3.5 | -1.6 | -5.0 | -6.7 | -15.8 | · | · | · | |
| EV / EBITDA | -8.3 | · | -8.6 | -2.0 | -0.1 | · | · | · | · | · | · | · | |
| EV / FCF | -10.2 | · | -10.0 | -2.2 | -0.1 | · | · | · | · | · | · | · | |
| Earnings Yield | -8.8% | -15.6% | -7.0% | -16.1% | -25.8% | · | · | · | · | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SG&A Expense | $19M | $16M | $13M | $10M | $11M | $9M | $8M | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $3M | $2M | |
| Operating Expenses | $41M | $39M | $33M | $30M | $31M | $28M | $31M | $26M | $23M | $22M | $18M | $18M | $12M | $12M | $11M | $11M | |
| Operating Income | $-41M | $-39M | $-33M | $-30M | $-31M | $-28M | $-31M | $-26M | $-23M | $-22M | $-18M | $-18M | $-12M | $-12M | $-11M | $-11M | |
| Other Non-op | $737.0K | $2M | $1M | $694.0K | $1M | $2M | $2M | $2M | $947.0K | $2M | $2M | $1M | $778.0K | $2M | $575.0K | $149.0K | |
| Pretax Income | · | · | · | · | · | $-27M | · | · | · | $-20M | · | · | · | · | · | · | |
| Net Income | $-40M | $-37M | $-32M | $-30M | $-30M | $-27M | $-29M | $-24M | $-22M | $-20M | $-16M | $-17M | $-11M | $-11M | $-10M | $-10M | |
| EPS (Basic) | $-0.16 | $-0.15 | $-0.13 | $-0.14 | $-0.14 | $-0.12 | $-0.14 | $-0.11 | $-0.12 | $-0.11 | $-0.09 | $-0.10 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | |
| EPS (Diluted) | $-0.16 | $-0.15 | $-0.13 | $-0.14 | $-0.14 | $-0.12 | $-0.14 | $-0.11 | $-0.12 | $-0.11 | $-0.09 | $-0.10 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | |
| Shares (Basic) | 253,569,891 | 253,280,551 | · | 216,462,161 | 216,431,348 | 216,146,934 | · | 211,847,651 | 182,584,078 | 182,550,109 | · | 174,696,191 | 152,796,617 | 152,781,580 | · | 152,773,015 | |
| Shares (Diluted) | 253,569,891 | 253,280,551 | · | 216,462,161 | 216,431,348 | 216,146,934 | · | 211,847,651 | 182,584,078 | 182,550,109 | · | 174,696,191 | 152,796,617 | 152,781,580 | · | 152,773,015 | |
| EBITDA | $-41M | $-39M | · | $-30M | $-31M | $-28M | · | $-26M | $-23M | $-22M | · | $-18M | $-12M | $-12M | · | $-11M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $42M | $39M | $33M | $16M | $17M | $20M | $15M | $21M | $24M | $17M | $27M | $28M | $23M | $34M | $52M | $120M | |
| Short-term Investments | $131M | $164M | $203M | $108M | $129M | $153M | $181M | $198M | $98M | $126M | $136M | $141M | $82M | $81M | $74M | $14M | |
| Prepaid Expense | $5M | $6M | $6M | $4M | $5M | $5M | $6M | $7M | $6M | $3M | $4M | $2M | $3M | $3M | $3M | $3M | |
| Current Assets | $178M | $209M | $242M | $128M | $151M | $177M | $202M | $226M | $128M | $146M | $166M | $170M | $108M | $118M | $129M | $137M | |
| PP&E (Net) | $641.0K | $130.0K | $100.0K | $85.0K | $119.0K | $138.0K | $165.0K | $206.0K | $236.0K | $248.0K | $270.0K | $277.0K | $264.0K | $47.0K | $51.0K | $59.0K | |
| PP&E (Gross) | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | |
| Accum. Depreciation | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | |
| Other Non-current Assets | $2M | $886.0K | $84.0K | $990.0K | $1M | $1M | $242.0K | $1M | $1M | $1M | $387.0K | $1M | $888.0K | $868.0K | $116.0K | $876.0K | |
| Total Assets | $192M | $222M | $253M | $141M | $164M | $189M | $213M | $239M | $140M | $158M | $178M | $182M | $120M | $129M | $140M | $148M | |
| Accounts Payable | $7M | $4M | $6M | $4M | $5M | $6M | $5M | $5M | $3M | $3M | $4M | $3M | $3M | $2M | $1M | $893.0K | |
| Accrued Liabilities | $11M | $11M | $15M | $13M | $9M | $6M | $10M | $8M | $8M | $7M | $7M | $6M | $3M | $3M | $5M | $4M | |
| Current Liabilities | $18M | $16M | $20M | $17M | $14M | $12M | $15M | $13M | $11M | $10M | $11M | $9M | $6M | $5M | $6M | $5M | |
| Capital Leases | · | · | · | · | · | · | · | · | · | · | · | $300.0K | · | · | · | · | |
| Other Non-current Liabilities | $770.0K | · | $0 | $0 | $0 | $44.0K | $87.0K | $128.0K | $169.0K | $208.0K | $247.0K | $284.0K | $20.0K | $37.0K | $54.0K | $71.0K | |
| Total Liabilities | $48M | $46M | $50M | $47M | $43M | $41M | $41M | $39M | $38M | $36M | $37M | $36M | $32M | $31M | $32M | $31M | |
| Long-term Debt | $30M | $30M | $30M | $30M | $30M | $30M | · | $27M | $26M | $26M | · | $26M | $26M | $26M | · | $26M | |
| Total Debt | $30M | $30M | · | $30M | $30M | $30M | · | $27M | $26M | $26M | · | $26M | $26M | $26M | · | $26M | |
| Common Stock | $204.0K | $204.0K | $204.0K | $173.0K | $173.0K | $173.0K | $173.0K | $172.0K | $140.0K | $140.0K | $140.0K | $137.0K | $116.0K | $116.0K | $116.0K | $116.0K | |
| Retained Earnings | $-686M | $-645M | $-608M | $-576M | $-546M | $-516M | $-489M | $-460M | $-436M | $-414M | $-393M | $-377M | $-361M | $-349M | $-339M | $-328M | |
| AOCI | $-534.0K | $-429.0K | $-87.0K | $-155.0K | $-216.0K | $-632.0K | $-750.0K | $299.0K | $-880.0K | $-742.0K | $-271.0K | $-942.0K | $-619.0K | $-461.0K | $-605.0K | $-2M | |
| Stockholders' Equity | $144M | $176M | $203M | $94M | $120M | $148M | $171M | $199M | $102M | $122M | $140M | $147M | $88M | $98M | $108M | $117M | |
| Liabilities + Equity | $192M | $222M | $253M | $141M | $164M | $189M | $213M | $239M | $140M | $158M | $178M | $182M | $120M | $129M | $140M | $148M | |
| Shares Outstanding | 205,399,365 | 204,922,140 | 204,567,283 | 172,850,443 | 172,836,922 | 172,703,390 | 172,423,223 | 170,842,763 | 138,199,047 | 138,176,641 | 138,143,545 | 135,339,836 | 114,150,455 | 114,064,736 | 114,046,345 | 114,042,642 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $28.0K | $24.0K | $-13.0K | $35.0K | $34.0K | $30.0K | $32.0K | $33.0K | $33.0K | $32.0K | $31.0K | $30.0K | $8.0K | $8.0K | $7.0K | $8.0K | |
| Stock-based Comp | $8M | $11M | $5M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $995.0K | $958.0K | $864.0K | $561.0K | $450.0K | |
| Operating Cash Flow | $-30M | $-33M | $-25M | $-23M | $-26M | $-27M | $-23M | $-23M | $-22M | $-21M | $-16M | $-13M | $-10M | $-12M | $-9M | $-8M | |
| CapEx | $222.0K | $54.0K | $2.0K | $2.0K | $15.0K | $3.0K | $-9.0K | $3.0K | $21.0K | $10.0K | $24.0K | $43.0K | $225.0K | $4.0K | $0 | $4.0K | |
| Investing Cash Flow | $33M | $39M | $-94M | $21M | $24M | $29M | $18M | $-98M | $30M | $11M | $7M | $-57M | $-1M | $-6M | $-59M | $33M | |
| Debt Issued | · | · | $0 | $0 | $0 | $30M | · | · | · | · | · | · | · | · | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | $2M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $189.0K | $-195.0K | $136M | $-23.0K | $-49.0K | $2M | $-843.0K | $118M | $55.0K | $49.0K | $8M | $75M | $104.0K | $26.0K | $1.0K | $-1.0K | |
| Net Change in Cash | $3M | $6M | $17M | $-1M | $-2M | $4M | $-6M | $-2M | $7M | $-10M | $-1M | $5M | $-11M | $-18M | $-68M | $25M | |
| Free Cash Flow | · | $-33M | · | · | · | $-27M | · | · | · | $-21M | · | · | · | $-12M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -22.6% | -18.1% | · | -15.6% | -20.0% | -15.3% | · | -11.5% | -17.1% | -14.1% | · | -10.1% | -8.3% | -7.1% | · | -6.2% | |
| ROE | -30.5% | -23.0% | · | -20.1% | -27.4% | -19.8% | · | -14.0% | -23.5% | -18.5% | · | -12.6% | -10.7% | -9.0% | · | -7.6% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.1 | 13.5 | · | 7.7 | 11.1 | 14.9 | · | 17.7 | 11.3 | 14.9 | · | 19.0 | 18.3 | 23.9 | · | 26.5 | |
| Quick Ratio | 9.8 | 13.0 | · | 7.4 | 10.7 | 14.5 | · | 17.2 | 10.8 | 14.6 | · | 18.8 | 17.9 | 23.3 | · | 26.0 | |
| Debt / Equity | 0.2 | 0.2 | · | 0.3 | 0.2 | 0.2 | · | 0.1 | 0.3 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.2 | |
| LT Debt / Equity | 0.2 | 0.2 | · | 0.3 | 0.2 | 0.2 | · | 0.1 | 0.3 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.2 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.70 | $0.86 | · | $0.55 | $0.70 | $0.86 | · | $1.17 | $0.74 | $0.88 | · | $1.08 | $0.77 | $0.86 | · | $1.02 | |
| Cash Flow / Share | · | $-0.13 | · | · | · | $-0.13 | · | · | · | $-0.11 | · | · | · | $-0.08 | · | · | |
| Cash / Share | $0.20 | $0.19 | · | $0.09 | $0.10 | $0.11 | · | $0.13 | $0.17 | $0.12 | · | $0.20 | $0.20 | $0.30 | · | $1.05 | |
| EPS (TTM) | $-0.58 | $-0.56 | · | $-0.54 | $-0.51 | $-0.49 | · | $-0.43 | $-0.42 | $-0.37 | · | $-0.31 | $-0.28 | $-0.27 | · | $-0.25 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-139M | $-129M | · | $-116M | $-110M | $-102M | · | $-83M | $-75M | $-64M | · | $-49M | $-43M | $-40M | · | $-39M | |
| Market Cap | $1.27B | $1.12B | · | $617M | $394M | $478M | · | $724M | $557M | $688M | · | $512M | $365M | $222M | · | $177M | |
| Enterprise Value | $1.12B | $946M | · | $522M | $277M | $335M | · | $531M | $462M | $571M | · | $370M | $286M | $134M | · | $69M | |
| P/E | -10.6 | -9.8 | · | -6.6 | -4.5 | -5.7 | · | -9.9 | -9.6 | -13.5 | · | -12.2 | -11.4 | -7.2 | · | -6.2 | |
| P/B | 8.8 | 6.4 | · | 6.5 | 3.3 | 3.2 | · | 3.6 | 5.5 | 5.6 | · | 3.5 | 4.2 | 2.3 | · | 1.5 | |
| P / Tangible Book | 8.8 | 6.4 | · | 6.5 | 3.3 | 3.2 | · | 3.6 | 5.5 | 5.6 | · | 3.5 | 4.2 | 2.3 | · | 1.5 | |
| P / Cash Flow | · | -33.9 | · | · | · | -17.6 | · | · | · | -33.3 | · | · | · | -18.5 | · | · | |
| Earnings Yield | -9.4% | -10.3% | · | -15.1% | -22.4% | -17.7% | · | -10.1% | -10.4% | -7.4% | · | -8.2% | -8.8% | -13.9% | · | -16.1% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Nettoergebnis | $-119M | $-96M | $-55M | $-38M | $-43M |
| Verwässerte EPS | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.1 | · | 0.2 | 0.2 | 0.2 |
| Liquiditätsgrad | 11.8 | · | 15.7 | 22.0 | 11.3 |
| Quick Ratio | 11.6 | · | 15.3 | 21.5 | 11.0 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-101M | · | $-51M | $-35M | $-40M |
Institutionelle Eigentümer (13F) 194 Einreicher · $1.4B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
194
Gehaltener Wert
$1.4B
Neue Positionen
23
Geschlossene Positionen
25
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 23 (-39 vs. Vorquartal) | 25 (+6 vs. Vorquartal) | 72 (+5 vs. Vorquartal) | 58 (+21 vs. Vorquartal) | +4.1M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| NEA Management Company, LLC | $150.742.986 | 24.471.264 | 10,78% | Aktien |
| Bain Capital Life Sciences Investors, LLC | $108.419.826 | 17.600.621 | 7,75% | Aktien |
| Venrock Adviser, LLC | $90.835.009 | 14.745.943 | 6,50% | Aktien |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $83.585.040 | 13.569.000 | 5,98% | Aktien |
| BlackRock, Inc. | $76.966.107 | 12.494.498 | 5,50% | Aktien |
| TCG Crossover Management, LLC | $76.151.183 | 12.362.205 | 5,45% | Aktien |
| VANGUARD GROUP INC | $60.551.132 | 10.041.647 | 4,33% | Aktien |
| Frazier Life Sciences Management, L.P. | $59.880.448 | 9.720.852 | 4,28% | Aktien |
| Polar Capital Holdings Plc | $58.777.402 | 9.541.786 | 4,20% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $48.864.477 | 7.932.545 | 3,49% | Aktien |
| Nantahala Capital Management, LLC | $42.977.150 | 6.976.810 | 3,07% | Aktien |
| STATE STREET CORP | $40.368.624 | 6.553.348 | 2,89% | Aktien |
| MARSHALL WACE, LLP | $38.543.053 | 6.256.989 | 2,76% | Aktien |
| RTW INVESTMENTS, LP | $36.666.661 | 5.952.380 | 2,62% | Aktien |
| Woodline Partners LP | $26.149.933 | 4.245.119 | 1,87% | Aktien |
| ORBIMED ADVISORS LLC | $24.392.984 | 3.959.900 | 1,74% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $23.857.705 | 3.872.133 | 1,71% | Aktien |
| Spruce Street Capital LP | $21.267.868 | 3.452.576 | 1,52% | Aktien |
| Rosalind Advisors, Inc. | $19.577.225 | 3.178.121 | 1,40% | Aktien |
| EMERALD ADVISERS, LLC | $19.394.384 | 3.148.439 | 1,39% | Aktien |
| Pictet Asset Management Holding SA | $17.020.419 | 2.763.055 | 1,22% | Aktien |
| Vestal Point Capital, LP | $16.755.200 | 2.720.000 | 1,20% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $16.600.042 | 2.694.812 | 1,19% | Aktien |
| D. E. Shaw & Co., Inc. | $15.492.388 | 2.514.998 | 1,11% | Aktien |
| Affinity Asset Advisors, LLC | $15.474.862 | 2.512.153 | 1,11% | Aktien |
| EMERALD MUTUAL FUND ADVISERS TRUST | $14.636.154 | 2.375.999 | 1,05% | Aktien |
| NAN FUNG TRINITY (HK) LTD | $11.348.876 | 1.842.350 | 0,81% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $10.076.762 | 1.635.838 | 0,72% | Aktien |
| ADAR1 Capital Management, LLC | $8.644.999 | 1.403.409 | 0,62% | Aktien |
| SILVERARC CAPITAL MANAGEMENT, LLC | $8.349.627 | 1.355.459 | 0,60% | Aktien |
| ALGERT GLOBAL LLC | $8.188.235 | 1.329.259 | 0,59% | Aktien |
| NORTHERN TRUST CORP | $8.025.894 | 1.302.905 | 0,57% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $7.211.802 | 1.170.747 | 0,52% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $6.412.597 | 1.041.006 | 0,46% | Aktien |
| Longaeva Partners L.P. | $6.257.864 | 1.015.887 | 0,45% | Aktien |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $6.219.696 | 1.009.691 | 0,44% | Aktien |
| SUPERSTRING CAPITAL MANAGEMENT LP | $6.021.154 | 977.460 | 0,43% | Aktien |
| DEUTSCHE BANK AG\ | $5.328.129 | 864.956 | 0,38% | Aktien |
| GOLDMAN SACHS GROUP INC | $5.108.767 | 829.345 | 0,37% | Aktien |
| SPHERA FUNDS MANAGEMENT LTD. | $4.657.970 | 756.164 | 0,33% | Aktien |
| Swedbank AB | $4.409.944 | 715.900 | 0,32% | Aktien |
| VOYA INVESTMENT MANAGEMENT LLC | $4.264.020 | 692.211 | 0,30% | Aktien |
| F/m Investments LLC | $4.055.461 | 658.354 | 0,29% | Aktien |
| Sio Capital Management, LLC | $3.804.878 | 617.675 | 0,27% | Aktien |
| AXA Investment Managers S.A. | $3.760.142 | 1.053.261 | 0,27% | Aktien |
| KVP Capital Advisors, LP | $3.728.525 | 605.280 | 0,27% | Aktien |
| Integral Health Asset Management, LLC | $3.696.000 | 600.000 | 0,26% | Aktien |
| BANK OF AMERICA CORP /DE/ | $3.205.393 | 520.356 | 0,23% | Aktien |
| UBS Group AG | $3.160.240 | 513.026 | 0,23% | Aktien |
| Moody Aldrich Partners LLC | $2.974.005 | 482.793 | 0,21% | Aktien |
Aktivisten & 5%+-Eigentümer 7 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Growth Equity Opportunities 17, LLC, New Enterprise Associates 17, L.P., NEA Partners 17, L.P., NEA 17 GP, LLC, Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad H. Makhzoumi, Edward T. Mathers, Scott D. Sandell, Paul Walker, Rick Yang ×4 Einreichungen | 14. November 2025 | 12,00% | Änderung | Passive Anlage | SEC |
| Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP, BCLS II Investco, LP ×5 Einreichungen | 27. März 2025 | 9,99% | Änderung | · | SEC |
| High River Limited Partnership, Hopper Investments LLC, Barberry Corp., Icahn Partners Master Fund LP, Icahn Offshore LP, Icahn Partners LP, Icahn Onshore LP, Icahn Capital LP, IPH GP LLC, Icahn Enterprises Holdings L.P., Icahn Enterprises G.P. Inc., Beckton Corp., Carl C. Icahn | 30. Dezember 2015 | · | Erste Einreichung | · | SEC |
| Evan M. Levine, Mark Capital, LLC | 6. Februar 2009 | · | Erste Einreichung | · | SEC |
| Evan Levine, Mark Capital, LLC ×2 Einreichungen | 19. Dezember 2007 | · | Erste Einreichung | · | SEC |
| Matthew Balk ×2 Einreichungen | 1. Juni 2006 | · | Erste Einreichung | Passive Anlage | SEC |
| High River Limited Partnership S.S. OR, Hopper Investments LLC S.S. OR, Barberry Corp. S.S. OR, Icahn Partners Master Fund LP S.S. OR, Icahn Offshore LP S.S. OR, CCI Offshore Corp. S.S. OR, Icahn Partners LP S.S. OR, Icahn Onshore LP S.S. OR, CCI Onshore Corp. S.S. OR, Carl C. Icahn S.S. OR | 5. August 2005 | · | Erste Einreichung | Vorstandskampagne | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 59 Insider · 31 Führungskräfte · 25 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Matthew Pauls | CHIEF EXECUTIVE OFFICER | 16. Dezember 2025 G | 1.188.050 | 0 | 0 | $0 |
| Robert N Neville | Chief Executive Officer | 20. Dezember 2019 A | 498.028 | 0 | 0 | $0 |
| Brian M Culley | CEO and Director | 20. Januar 2017 A | 34.500 | 0 | 0 | $0 |
| Evan Levine | CEO & President | 8. Februar 2008 P | 4.395.000 | 0 | 0 | $0 |
| Nicholas J Virca | CEO and President | 15. Dezember 2003 X | 347.956 | 0 | 0 | $0 |
| David L Lowrance | Chief Financial Officer | 22. Juni 2026 M | 536.032 | 0 | 1 | $-2.240.919 |
| Brandi Roberts | Chief Financial Officer & SVP | 20. Januar 2017 A | 38.000 | 0 | 0 | $0 |
| Mark Bagnall | CFO & Executive Vice President | 3. April 2008 A | · | 0 | 0 | $0 |
| Gregory P Hanson | Senior VP, CFO & Treasurer | 20. Dezember 2006 A | · | 0 | 0 | $0 |
| Carrie Carlander | CFO, Treas, Secy, VP Finance | 31. Januar 2006 A | 25.000 | 0 | 0 | $0 |
| Jaakko Taneli Jouhikainen | President and Chief Operating Officer | 20. Dezember 2019 A | 167.569 | 0 | 0 | $0 |
| Patrick L Keran | President & COO | 2. Januar 2015 A | · | 0 | 0 | $0 |
| James A Merritt | President & Chf Med Officer | 14. Dezember 2007 P | 35.000 | 0 | 0 | $0 |
| Braden C. Parker | Chief Commercial Officer | 24. September 2026 F | 75.677 | 0 | 0 | $0 |
| Robert Matthew Lutz | Chief Fin. & Operating Officer | 15. Juli 2026 A | 328.977 | 0 | 0 | $0 |
| Kathleen R. Mccabe | Chief Legal Officer | 14. Dezember 2025 F | 519.232 | 0 | 0 | $0 |
| Anne Erickson | Chief Business Officer | 14. Dezember 2025 F | 371.712 | 0 | 0 | $0 |
| Yasmine Wasfi | Chief Medical Officer | 4. Dezember 2025 F | 168.008 | 0 | 0 | $0 |
| Raymond Dennis Pratt | Chief Medical Officer | 12. Dezember 2024 A | 340.050 | 0 | 0 | $0 |
| Badrul A. Chowdhury | CHIEF MEDICAL OFFICER | 14. Dezember 2021 A | 300.000 | 0 | 0 | $0 |
| Shana Hood | General Counsel & VP | 20. Januar 2017 A | · | 0 | 0 | $0 |
| Edwin L. Parsley | Chief Medical Officer & SVP | 20. Januar 2017 A | · | 0 | 0 | $0 |
| Gregory D. Gorgas | Senior VP, Commercial | 4. Januar 2016 A | · | 0 | 0 | $0 |
| Robert Martin Emanuele | Senior VP, Development | 4. Januar 2016 A | 294.598 | 0 | 0 | $0 |
| Santosh Vetticaden | Chief Medical Officer & SVP | 19. Juni 2014 A | · | 0 | 0 | $0 |
| Mark E. Erwin | SVP, Operations | 30. Januar 2009 A | · | 0 | 0 | $0 |
| Michele Yelmene | VP, Regulatory & QA | 30. Januar 2009 A | · | 0 | 0 | $0 |
| Joan M Robbins | CSO, Sr. VP | 14. Mai 2008 P | 10.000 | 0 | 0 | $0 |
| Joachim Ph Schupp | VP, Medical Affairs | 31. März 2008 A | · | 0 | 0 | $0 |
| Mark Joseph Cantwell | VP, Research & Development | 12. Januar 2007 A | · | 0 | 0 | $0 |
| Cellia Habita | Senior VP, Clinical & Medical | 7. Oktober 2004 P | 5.000 | 0 | 0 | $0 |
| Joseph S Mccracken | Direktor | 16. Februar 2026 M | 302.644 | 0 | 0 | $0 |
| David A Ramsay | Direktor | 19. Dezember 2025 S | 2.533.642 | 0 | 1 | $-121.200 |
| An Van Es-Johansson | Direktor | 9. Dezember 2025 A | 102.500 | 0 | 0 | $0 |
| Nevan C Elam | Direktor | 9. Dezember 2025 A | 106.887 | 0 | 0 | $0 |
| Richard J Hawkins | Direktor | 9. Dezember 2025 A | 161.326 | 0 | 0 | $0 |
| Ricky Sun | Direktor | 14. Dezember 2023 A | 22.500 | 0 | 0 | $0 |
| Yuri Pikover | Direktor | 13. Dezember 2018 A | 153.734 | 0 | 0 | $0 |
| Peter Greenleaf | Direktor | 20. Januar 2017 A | · | 0 | 0 | $0 |
| DITTRICH HOWARD | Direktor | 20. Januar 2017 A | · | 0 | 0 | $0 |
| Lewis Shuster | Direktor | 11. Juni 2015 A | · | 0 | 0 | $0 |
| Jack Lief | Direktor | 11. Juni 2015 A | · | 0 | 0 | $0 |
| Ted W Love | Direktor | 19. Juni 2013 A | · | 0 | 0 | $0 |
| Odysseas D Kostas | Direktor | 30. Juni 2010 A | · | 0 | 0 | $0 |
| Eric K Rowinsky | Direktor | 30. Juni 2010 A | · | 0 | 0 | $0 |
| Mark Jerome Pykett | Direktor | 30. Juni 2010 A | 8.000 | 0 | 0 | $0 |
| Michael M Goldberg | Direktor | 30. Juni 2010 A | 26.000 | 0 | 0 | $0 |
| DENNER ALEXANDER J | Direktor | 30. Juni 2008 A | · | 0 | 0 | $0 |
| Ross M Johnson | Direktor | 21. Dezember 2006 X | 1.621.779 | 0 | 0 | $0 |
| Meister, Keith A. | Direktor | 2. Juni 2006 A | · | 0 | 0 | $0 |
| Rick Yang | 10%-Eigentümer | 17. Juli 2023 P | 24.471.264 | 0 | 0 | $0 |
| Carmen Chang | 10%-Eigentümer | 17. Juli 2023 P | 24.471.264 | 0 | 0 | $0 |
| Mohamad Makhzoumi | 10%-Eigentümer | 17. Juli 2023 P | 24.471.264 | 0 | 0 | $0 |
| Ali Behbahani | 10%-Eigentümer | 17. Juli 2023 P | 24.471.264 | 0 | 0 | $0 |
| Anthony A. Florence, Jr. | 10%-Eigentümer | 17. Juli 2023 P | 24.471.264 | 0 | 0 | $0 |
| Paul Walker | 10%-Eigentümer | 17. Juli 2023 P | 24.471.264 | 0 | 0 | $0 |
| Edward T. Mathers | 10%-Eigentümer | 17. Juli 2023 P | 24.471.264 | 0 | 0 | $0 |
| Forest Baskett | 10%-Eigentümer | 17. Juli 2023 P | 24.471.264 | 0 | 0 | $0 |
| Scott D. Sandell | 10%-Eigentümer | 17. Juli 2023 P | 24.471.264 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 27 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,70% | 59.090 NS | 31. Juli 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,62% | 409.369 NS | 31. Juli 2026 | N-PORT |
| IWC · iShares Trust | 0,19% | 520.275 SH | 11. September 2026 | Täglich |
| LABU · Direxion Shares ETF Trust | 0,12% | 108.602 NS | 31. Juli 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,09% | 301.950 SH | 19. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,07% | 14.661 SH | 2. Oktober 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,06% | 163.980 SH | 19. August 2026 | Täglich |
| IWO · iShares Trust | 0,05% | 1.436.801 SH | 11. September 2026 | Täglich |
| IBB · iShares Trust | 0,04% | 822.223 SH | 11. September 2026 | Täglich |
| PWS · Pacer Funds Trust | 0,03% | 1.484 NS | 31. Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,03% | 880.662 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,03% | 73.241 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,03% | 3.929.899 SH | 11. September 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 103.677 SH | 2. Oktober 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1.567.813 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,01% | 277.850 SH | 19. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 43.814 NS | 31. Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,01% | 12.952 SH | 10. September 2026 | Täglich |
| TILT · FlexShares Trust | 0,00% | 19.118 NS | 31. Juli 2026 | N-PORT |
| WSML · iShares Trust | 0,00% | 5.664 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 43.112 SH | 11. September 2026 | Täglich |
| ITOT · iShares Trust | 0,00% | 170.809 SH | 11. September 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,00% | 23.796 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 6.164.961 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 11.396 SH | 19. August 2026 | Täglich |
| ISCB · iShares Trust | · | 4.332 SH | 11. September 2026 | Täglich |
| ISCV · iShares Trust | · | 11.041 SH | 11. September 2026 | Täglich |
SVRA Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 14 Analysten
KAUF
Median-Ziel
$10.25
+113,1%
5 35,7%
Starker Kauf
8 57,1%
Kauf
1 7,1%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
8 Analysten · 2026-09-28Mittelwert-Ziel $10.94 +127,4%
← Unter allen Zielen
Aktueller Preis $4.81
Tief$9.00
Mittelwert$10.94
Hoch$16.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| SVRA | $1.23B | -11.4 | · | · | -73.4% | · |
| JANX | $833M | -7.5 | -5.5% | -1136.2% | -11.7% | · |
| AKTS | · | · | · | · | · | · |
| CGEM | $624M | -3.2 | · | · | -44.0% | · |
| ODTX | · | · | · | · | · | · |
| KURA | $913M | -3.3 | 25.2% | -413.0% | -116.2% | · |
| CRVS | $575M | -14.5 | · | · | -21.6% | · |
| JBIO | $761M | -4.8 | · | · | -47.7% | · |
| GLUE | $1.03B | · | 63.5% | -31.2% | -15.4% | · |
| RIGL | $784M | 2.2 | 64.1% | 124.7% | 155.1% | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 11, 2026